| scholarly article | Q13442814 |
| P356 | DOI | 10.4088/JCP.V63N0611 |
| P698 | PubMed publication ID | 12088166 |
| P50 | author | Andrea Fagiolini | Q42651594 |
| Daniel J Buysse | Q90217822 | ||
| Patricia R Houck | Q109322409 | ||
| David Kupfer | Q5236159 | ||
| P2093 | author name string | Ellen Frank | |
| Holly A. Swartz | |||
| Hernando Ombao | |||
| Alan G. Mallinger | |||
| P433 | issue | 6 | |
| P921 | main subject | obesity | Q12174 |
| patient | Q181600 | ||
| P304 | page(s) | 528-533 | |
| P577 | publication date | 2002-06-01 | |
| 2002-06-15 | |||
| P1433 | published in | The Journal of Clinical Psychiatry | Q7743563 |
| P1476 | title | Prevalence of Obesity and Weight Change During Treatment in Patients With Bipolar I Disorder | |
| Prevalence of obesity and weight change during treatment in patients with bipolar I disorder | |||
| P478 | volume | 63 |
| Q47285127 | A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders |
| Q36193578 | A prospective observational study of obesity, body composition, and insulin resistance in 18 women with bipolar disorder and 17 matched control subjects |
| Q40842714 | Abdominal obesity is associated with impaired cognitive function in euthymic bipolar individuals |
| Q35690464 | An Integrated Risk Reduction Intervention can reduce body mass index in individuals being treated for bipolar I disorder: results from a randomized trial |
| Q48908840 | An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses |
| Q34655996 | Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study |
| Q38077281 | Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice |
| Q36302677 | Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring |
| Q38974619 | Bariatric surgery in patients with bipolar spectrum disorders: Selection factors, postoperative visit attendance, and weight outcomes |
| Q36795172 | Biological aging alters circadian mechanisms in murine adipose tissue depots |
| Q57533247 | Bipolar disorder and adiposity: a study using whole body dual energy X-ray absorptiometry scans |
| Q37207249 | Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden |
| Q35940844 | Bipolar disorder: a national health concern. |
| Q47913705 | Body mass index associates with white matter microstructure in bipolar depression. |
| Q36532159 | Can body mass index help predict outcome in patients with bipolar disorder? |
| Q34588960 | Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. |
| Q36108130 | Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States |
| Q51854870 | Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent-onset bipolar disorder. |
| Q36764413 | Circadian rhythms and the regulation of metabolic tissue function and energy homeostasis. |
| Q34067376 | Comorbid mood, psychosis, and marijuana abuse disorders: a theoretical review |
| Q37484086 | Correlates of metabolic abnormalities in bipolar I disorder at initiation of acute phase treatment |
| Q46444268 | Depressive symptoms during childhood and adult obesity: the Zurich Cohort Study |
| Q33601890 | Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder. |
| Q36502629 | Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target? |
| Q44983319 | Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics |
| Q47915978 | Eveningness and Its Associated Impairments in Remitted Bipolar Disorder |
| Q37422118 | Fat circadian biology |
| Q34208829 | Human sodium-coupled citrate transporter, the orthologue of Drosophila Indy, as a novel target for lithium action |
| Q53159774 | Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. |
| Q37896630 | Insulin dysfunction and allostatic load in bipolar disorder |
| Q46367455 | Lithium inhibits brown adipocyte differentiation. |
| Q36262539 | Lithium: a review of its metabolic adverse effects |
| Q36433993 | Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis |
| Q47249575 | Lower cognitive functioning as a predictor of weight gain in bipolar disorder: a 12-month study. |
| Q35236970 | Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities |
| Q34034971 | Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome |
| Q34137064 | Metabolic dysfunction in women with bipolar disorder: the potential influence of family history of type 2 diabetes mellitus |
| Q43093860 | Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses |
| Q46714706 | Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians |
| Q36400968 | Metabolic syndrome in bipolar disorders |
| Q36664112 | Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial |
| Q35836912 | Mood disorder symptoms and elevated cardiovascular disease risk in patients with bipolar disorder |
| Q30897232 | Neurocognitive functioning in overweight and obese patients with bipolar disorder: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM) |
| Q38160202 | Obesity and bipolar disorder: synergistic neurotoxic effects? |
| Q36751327 | Obesity and the three-year longitudinal course of bipolar disorder |
| Q51785668 | Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. |
| Q47704381 | Obesity in patients with major depression is related to bipolarity and mixed features: evidence from the BRIDGE-II-Mix study |
| Q38266743 | Obesity is associated with previous suicide attempts in bipolar disorder |
| Q78746743 | Pharmacoepidemiology and drug safety |
| Q36832356 | Phentermine, sibutramine and affective disorders. |
| Q34024177 | Preliminary findings regarding overweight and obesity in pediatric bipolar disorder |
| Q34181934 | Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review |
| Q46756223 | Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder |
| Q45249093 | Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study |
| Q46776702 | Psychogenic nonepileptic seizures are associated with an increased risk of obesity |
| Q35843533 | Psychotropic drugs in the treatment of obesity: what promise? |
| Q36417680 | Rapid adipose deposition with mood disorders |
| Q96773913 | Role of obesity in systemic low-grade inflammation and cognitive function in patients with bipolar I disorder or major depressive disorder |
| Q35618441 | Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. |
| Q34626687 | Season of birth is associated with adult body mass index in patients with bipolar disorder |
| Q48617350 | Selected cytokine profiles during remission in bipolar patients |
| Q36401125 | Sleep apnea risk and clinical correlates in patients with bipolar disorder |
| Q34504582 | Sleep quality during euthymia in bipolar disorder: the role of clinical features, personality traits, and stressful life events |
| Q47559940 | Socioeconomic Disparities and Metabolic Risk in Veterans with Serious Mental Illness. |
| Q38049775 | Spanish consensus on physical health of patients with bipolar disorder |
| Q35884715 | The Metabolic Syndrome in Patients With Severe Mental Illnesses |
| Q33702652 | The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). |
| Q35167517 | The burden of obesity among adults with bipolar disorder in the United States |
| Q37351069 | The effect of bariatric surgery on psychiatric course among patients with bipolar disorder |
| Q33772123 | The health benefits and challenges of exercise training in persons living with schizophrenia: a pilot study |
| Q36235502 | The safety and tolerability of atypical antipsychotics in bipolar disorder |
| Q54452819 | Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. |
| Q34769527 | Undiagnosed Bipolar Disorder: New Syndromes and New Treatments |
| Q38031006 | Weight changes and characteristics of patients associated with weight gain during inpatient psychiatric treatment |
| Q42682470 | Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records |
| Q37171035 | Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. |
| Q38838191 | Weight gain with add-on second-generation antipsychotics in bipolar disorder: a naturalistic study |
| Q34543946 | Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management |
| Q86430227 | [Affective disorders: endocrine and metabolic comorbidities] |
Search more.